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This study proposes a novel dual S-shaped logistic model for automatically quantifying the characteristic kinetic curves of 
breast lesions and for distinguishing malignant from benign breast tumors on dynamic contrast enhanced (DCE) magnetic res-
onance (MR) images. D(, ) is the diagnostic parameter derived from the logistic model. Significant differences were found 
in D(, ) between the malignant benign groups. Fisher’s Linear Discriminant analysis correctly classified more than 90% of 
the benign and malignant kinetic breast data using the derived diagnostic parameter (D(, )). Receiver operating characteris-
tic curve analysis of the derived diagnostic parameter (D(, )) indicated high sensitivity and specificity to differentiate ma-
lignancy from benignancy. The dual S-shaped logistic model was effectively used to fit the kinetic curves of breast lesions in 
DCE-MR. Separation between benign and malignant breast lesions was achieved with sufficient accuracy by using the derived 
diagnostic parameter D(, ) as the lesion’s feature. The proposed method therefore has the potential for computer-aided di-
agnosis in breast tumors. 
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Breast cancer is one of the most frequently diagnosed can-
cers in women, with a mortality rate second only to lung 
cancer [1]. Each year, over 1.2 million women develop in-
vasive breast cancer and more than 500000 die of this dis-
ease worldwide. With the rapid advancement of medical 
technology, especially in functional imaging and evaluation 
methods, the mortality rate of breast cancer has experienced 
a steady decrease of 3.2% per year among women less than 
50 years of age, and 2.0% among women greater than 50 
years of age, since 1990 [2]. Still, effective early detection 
of breast cancer that aims to identify lesions before symp-
toms develop is a key factor in the continual improvement 
of survival rates.  
Dynamic contrast enhanced magnetic resonance imaging 
(DCE-MRI) is a functional evaluation approach that char-
acterizes blood vessels and tissues by comparing magnetic 
resonance images acquired before and after intravenous 
injection of the contrast agent gadolinium. Through a series 
of key studies, it has gradually been recognized as serving 
an important role in quantitative functional evaluation of 
breast cancer. For example, DCE-MRI has been used to 
investigate suspicious micro calcifications either in isolation 
or associated with a breast mass on mammography [3,4], to 
stage loco-regional tumors in patients with primary malig-
nancy [5], and to predict and monitor pretreatment tumor 
response to neo-adjuvant chemotherapy [6–8]. In addition, 
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DCE-MRI has the potential to differentiate between malig-
nant and benign lesions [9–12]. Because of the complexity 
involved in interpreting the data, effective quantification of 
DCE-MRI is crucial to accurate diagnosis, and treatment 
evaluation of breast cancer in the clinical setting. 
Most of the existing DCE-MRI quantitative evaluation 
methods examine the kinetic curves formed by connecting 
the average enhancement over time within a region of in-
terest (ROI) defined by a human observer over the suspect-
ed lesion area. Previous DCE-MRI data analysis approaches 
include pharmacokinetics model and kinetic enhancement 
curve fitting.  
Pharmacokinetics models, constructed upon the filtration 
of contrast agents into lesion tissues, retrieve physiological 
information such as blood perfusion, capillary leakage, wa-
ter exchange rate, diffusion and microvasculature from the 
characteristics of the kinetic curves [13–15]. In the model 
proposed by Tofts and Kermode [13], physiological param-
eters are extracted such as the transcapillary transfer from 
plasma into interstitial space (Ktrans), the efflux transcapil-
lary transfer rate constant (Kep), and the volume of extra-
vascular extracellular space (EES) per unit volume of tissue 
(Ve). In this approach, pathological patterns of the lesions 
are reflected in the physiological features of the contrast 
agent kinetics, independent of imaging conditions. However, 
pharmacokinetics models based on feature extraction 
methods have their own limitations. For instance, they do 
not effectively address pressure gradients associated with 
fluid and solute transport in tissues, which may bring sig-
nificant deviations when the model is applied to tumors 
exhibiting high interstitial fluid pressure (IFP) [16]. Also, 
the difficulty in drawing the baseline T1 relaxation rate, 
which is a key factor in converting signal intensity to con-
trast agent concentration, introduces errors. In addition, the 
estimation of the arterial input function (AIF) involved in 
signal intensity conversion varies for different ROI loca-
tions, causing discrepancies among different physiological 
models. 
Kinetic curve fitting approaches are based upon the rela-
tionship between the shape of the kinetic curves and the 
degree of malignancy of the lesions. The breast imaging 
reporting and data system (BI-RADS) lexicon [17] catego-
rized kinetic enhancement curves into three types based on 
their initial rise and delayed phase (type I: persistent in-
crease; type II: maintains a plateau after initial increase; 
type III: rapid washout after initial increase). A previous 
study [18] showed that most benign lesions always maintain 
successive enhancement during the measured time course 
(type I) whereas malignant lesions frequently demonstrate 
rapid washout after the initial increase (type III). In the 
semi-quantitative model proposed by Szabo et al. [19], the 
maximum contrast enhancement, time to peak enhancement, 
and the descriptor of margins were extracted to distinguish 
between malignant and benign lesions. Unfortunately, this 
method is susceptible to noise [20], and inconsistencies be-
tween the parameters acquired under different experimental 
conditions have affected its clinical viability. Heiburg et al. 
[21] applied a fifth-order polynomial to simulate DCE-MRI 
data. A logistic model [22] was introduced by Moate et al. 
for kinetic curve fitting. These proposed models well pre-
dicted all three types of kinetic curves categorized by the 
BI-RADS lexicon, and were verified against clinic diagnos-
tic values of the parameters in the models. However, no 
quantitative results have been given to support the feasibil-
ity of this approach in differentiating between malignant 
and benign lesions. 
In this retrospective study, a modified, 4-variable quanti-
tative model derived from a classical logistic equation (dual 
S-shaped logistic model) is introduced to investigate 
DCE-MRI kinetic curves of breast lesions. Fitting parame-
ters  and  were extracted in an attempt to distinguish be-
tween malignant and benign lesions in 2-D parameter space. 
Sensitivity and specificity to malignant lesions using the 
derived diagnostic parameter D(, ) was evaluated by 
using receiver operating characteristic (ROC) analysis.  
1  Materials and methods 
1.1  Patient population 
DCE-MRI data from 50 female patients (mean age (53.1± 
10.6) years, range 29–70 years) were acquired consecutive-
ly between August 2008 and June 2011 as approved by the 
local ethics committee. Analysis was performed retrospec-
tively. Based on the consensus opinion of two pathologists 
and two radiologists, each with three years of experience, 
there were 25 benign and 25 malignant lesions investigated 
in this study. The diagnoses of all 50 subjects were con-
firmed pathologically. 
1.2  MR imaging protocol 
Subjects were scanned in a prone position using a standard 
double-breast coil on a 1.5 T whole-body MRI system 
(Signa; GE Medical Systems, Milwaukee, Wisconsin, USA). 
T1-weighted 3D spoiled gradient echo sequence with fat 
suppression was used in the DCEMR imaging using the 
following parameters: repetition time (TR), 6.9 ms, echo-      
time (TE), 2.7 ms, flip angle, 15°; field of view (FOV), 320 
mm×320 mm; matrix, 512×512; slice thickness, 2.4 mm. 
After the acquisition of the pre-contrast series, gadolini-
um-diethylene triamine pentaacetic acid (Gd-DTPA) as the 
contrast agent was delivered intravenously by power injec-
tion with a dose of 0.2 mL km1 body weight and a flow 
rate of 2 mL s1. 
1.3  ROI analysis 
To generate the kinetic curve, a 9-pixel square mask was 
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used to select the area which was perceived to be the most 
enhancing part of the lesion on the first post-contrast im-
age. The average signal intensity versus time was then 
calculated, yielding six data points on the kinetic curve of 
each ROI. 
1.4  Time phase 
Six to eight time phases of post-contrast images were ac-
quired after pre-contrast images and one time phase ob-
tained before injection, resulting in 7–9 data points on each 
kinetic curve. The scan time of each time phase was 60 s 
and there was no interval between time phases. 
1.5  Dual S-shaped logistic model 
A standard logistic model (eq. (1)) was used to describe the 







   (1) 
where SI is the signal intensity at time t and C is the ampli-
tude of the plateau of the curve. This model is able to pre-
dict persistent increase (type I) and sigmoid (type II) growth 
patterns. In this dual S-shaped logistic model, an additional 
term (1 )tme   is introduced to fit the washout phase of 














   (2) 
where SI is the signal intensity,  (min1) denotes the rate of 
signal decrease,  (min1) represents the rate of signal in-
crease, m and n are related to the upper and lower limit of 
the signal intensity, and t refers to the time phase of imaging, 
which ranges from 1 to 6. Based on this proposed model, 
unconstrained nonlinear optimization was performed to 
generate coefficients (m, n,  and ) to fit the kinetic 
curves.  
Because different patterns of kinetic curves reflect vari-
ous histopathologic properties of the breast lesion [23–26], 
 and  denoting the rate of signal decrease and signal in-
crease, respectively, are the main factor influencing the pat-
tern of the kinetic curve. Therefore, we extracted  and  as 
2-D features of the breast lesion. The feature parameters ( 
and ) were combined as D(, ) by using a linear equation. 
The most widely described features of DCE MRI analy-
sis are the uptake and wash-out patterns of the contrast 
agent in regions of suspected lesion [18]. Therefore, the 
up-slope (the maximum point-to-point enhancement slope) 
and tail-slope (the slope of a regression over the final few 
time-points) of kinetic curves were calculated to compare 
the diagnostic accuracy with the diagnostic parameter D(, 
) derived from our model.  
1.6  Statistical analysis 
The fitting coefficient R2 was calculated for each patient as 




























where SIOi and SIFi are the signal intensities of the original 
kinetic curve and the fitted curve, respectively. OSI  is the 
mean value of SIOi and N is the number of the time phase. 
An independent samples t-test was performed between two 
groups for each variable (D(, ), up-slope and tail-slope).  
Fisher’s Linear Discriminant (FLD) analysis was used to 
classify the kinetic curves into two groups (benign and ma-
lignant), in which the original multi-dimensional dataset 
was projected onto a one-dimensional straight line to max-
imize the inter-class distance and minimize the distance 
between class members. The separation S between these 
two classes is defined as the ratio of the variance between 
the classes 2between( )  to the variance within the classes 
2




















   












   









y y   are the means 
and covariances of two classes, respectively. y i  
 
 is 
the mean and 
T
y i
    is the variance for i=0, 1 of the 
linear combination of features x   . 
Classification performance and diagnostic accuracy for 
the combined parameter D(, ) and empirical parameters 
(up-slope and tail-slope) were evaluated by Receiver Oper-
ating Characteristic (ROC) analysis. The area under the ROC 
curve (AUC) was used as an index to evaluate the inherent 
distinguishing capacity among benign and malignant lesions. 
A P-value of less than 0.05 was considered statistically sig-
nificant. Sensitivity and specificity were calculated to eval-
uate the performance of a binary classification test.  
1.7  Steps involved in our dual S-shaped logistic model  
(i) The average DCE-MRI signal intensity as a function of 
time (SI(t)) in the selected ROI was calculated. 
(ii) Convert signal to relative enhancement (ignoring T1 
issues): signal/baseline–1. 
(iii) Fit the kinetic curve SI using the dual S-shaped lo-
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gistic model following eq. (1). The initial values of , , m 
and n were 0.1, 2, 1, 1. Unconstrained nonlinear optimiza-
tion was used to find the minimum of a scalar function of 
several variables, starting at the initial estimate. 
(iv) Extract  and  as characteristic features of the curve, 
which reveal the rate of signal increase and the rate of sig-
nal decrease. 
(v) Map all curves onto points in 2-D parameter space by 
using their features ( and ) as coordinates. 
(vi) Classify the points assuming a binary outcome (be-
nign and malignant). 
(vii) Calculate the up-slope (the maximum point-to-point 
slope) and tail-slope (the slope of a regression over the final 
three time-points) of the kinetic curves.  
(viii) Classification performance and diagnostic accuracy 
for the D(, ), up-slope and tail-slope were evaluated by 
ROC analysis. 
2  Results 
To obtain a prediction of a kinetic curve’s type, feature pa-
rameters ( and ) for the curve were entered into a linear 
regression model. On the basis of Fisher’s Linear Discrimi-
nant analysis of this model, the equation for the probable 
type of a kinetic curve was obtained as follows: 
 D( , ) 0.7079 0.2921 .        (5) 
In our study, 14 malignant lesions were associated with 
type III curves (washout) which exhibit a decreasing pattern. 
Eight malignant lesions and six benign lesions were associ-
ated with type II curves (plateau) which reach a plateau af-
ter an initial increase. Nineteen identified benign lesions 
and three malignant lesions were associated with type I 
(persistent) curves which demonstrate a continuous increase 
in enhancement with the measurement time.  
The curves of all 50 subjects (22 type I, 14 type II and 14 
type III), fitted with the dual S-shaped logistic model, 
yielded an average fitting coefficient R2 of 0.98 for type I 
(Figure 1A), 0.96 for type II (Figure 1B) and 0.93 for type 
III (Figure 1C). 
Figure 2A illustrates the statistical distribution of the 
combined parameter D(, ). Table 1 gives the means and 
standard deviations (SDs) of D(, ), up-slope and 
tail-slope for the ROIs, which reveal that the mean values of 
D(, ) and up-slope of the malignant ROIs are consistent-




Figure 1  Typical type I kinetic curve of benign lesions (A), typical type II kinetic curve (B) and type III kinetic curve (C) of malignant lesions fitted using 
the dual S-shaped logistic model. 
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Figure 2  Box-plots of statistical distributions for D(, ) (A), up-slope 
(B) and tail-slope (C) in benign lesions and malignant lesions. Lines in the 
boxes represent median values. Whiskers extended from the boxes indicate  
the range of 1.5×interquartile range (IQR) of the data. 
Table 1  The means and SDs of D(, ), up-slope and tail-slope in be-
nign (25 ROIs) and malignant (25 ROIs) ROIsa) 
Extracted 
parameters 
Benign (ROIs) Malignant (ROIs) P-value 
D(, ) 1.046±0.425 2.782±0.109 <0.001 
Up-slope 4.043±2.104 9.304±2.904 <0.001 
Tail-slope 0.041±0.072 0.079±0.071 <0.001 
a) P-values calculated with two-sample t-tests were used to identify 
significant differences between each variable obtained in benign and ma-
lignant regions of interest (ROIs). Data presented are mean±standard devi-
ation (SD). 
 
Group differences were observed for D(, ) (P<0.001), 
up-slope and tail-slope (Table 1). For all 50 subjects, FLD 
was used as a classifier, in which more than 90% of the be-
nign and malignant ROI data were classified correctly. The 
clear partition (Figure 3) indicated that the data for the benign 
and malignant ROIs were well separated in parameter space. 
To evaluate diagnostic performance, ROC curves were 
generated for all parameters as shown in Figure 4, with cal-
culated Az (area under the curve) values (Table 2). The pa-
rameter tail-slope had the smallest area under the ROC 
curve (Az=0.104), while the combined parameter D(, ) 
had the largest (Az=0.996). From these ROC curves we can 
see that the sensitivity and specificity of D(, ) to classify 
malignant lesions was better than that of the up-slope and  
 
 
Figure 3  Classification result of benign and malignant lesions’ kinetic 
curves using Fisher’s Linear Discriminant (FLD) with α and β as the ab- 
scissa and ordinate axes, respectively. 
 
Figure 4  ROC curves obtained from the combined parameter of D(, ), 
up-slope and tail-slope in the classification of benign and malignant lesions. 
Table 2  Statistical evaluation of using D(, ), up-slope and tail-slope in 
the classification of benign (25 ROIs) and malignant (25 ROIs) lesionsa) 
Measurement Area under curve (Az) P-value 
Az (D(, )) 0.996±0.004 <0.001 
Az (up-slope) 0.916±0.045 <0.001 
Az (tail-slope) 0.104±0.043 <0.001 
a) P-values calculated with Z-tests were used to identify the significant 
differences between the estimated Az and an Az value of 0.5. 
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tail-slope.  
3  Discussion 
DCE-MRI data, acquired before and after the injection of 
contrast agent to evaluate the vascular characteristics of 
tissues [27–30], have been widely applied in the early de-
tection of breast cancer. A dual S-shaped logistic model that 
is able to simulate the decaying phase was constructed in 
this retrospective study. It effectively quantified the breast 
lesion’s kinetic curves based on DCE-MRI data and distin-
guished between benign and malignant breast lesions. 
The enhancement mechanism of breast DCE-MRI is 
based on the paramagnetism of contrast agents. Such agents 
cause an initial increase in T1 and T2 relaxation rates of 
bulk water protons that is directly proportional to the con-
centration of contrast agents. After the initial increase, dif-
ferent patterns of contrast enhancement are demonstrated 
that reflect various histopathologic properties of the breast 
lesion, including vascular permeability factor (VPF), vas-
cular endothelial growth factor (VEGF) and extracellular 
fluid volume [31–33]. In particular, VEGF, which is se-
creted by malignant lesions, is directly related with neoan-
giogenesis, bringing more blood supply in malignant lesions 
than benign lesions. Higher water content in tumor tissues, 
as well as their higher capillary permeability induced by 
underdeveloped blood vessel endothelium, contributes to a 
faster water exchange and diffusion rate [34–36]. As a result, 
concentration of contrast agent in malignant tissues de-
creases (washout phase) after an initially rapid growth dur-
ing the measured time course, whereas the signal in benign 
lesions presents a persistent increase or plateau.  
For the aforementioned reasons, DCE-MRI kinetic data 
are closely related with pathologic characteristics of breast 
lesions. Previous studies [3–12] have demonstrated that 
effective quantification of DCE-MRI data is crucial to di-
agnosis, inspection, and treatment assessment of breast 
cancer in clinic. In that sense, a subjective evaluation tool 
that retrieves features from DCE-MRI kinetic data for lesion 
classification is strongly favored.  
Among the available feature extraction configurations 
based on the shape of lesion’s kinetic curves, pharmacoki-
netics models were first demonstrated [13–15], which evalu-
ate physiological parameters of lesion tissue from contrast 
agent concentration, converted from the signal intensity of 
images. Generally, pharmacokinetics models are composed 
of three parts: the AIF, the arterial output function (contrast 
agent concentration vs. time), and the simulation function. 
Embedded inaccuracies of this model result from uncertain-
ties associated with AIF estimation and T1 baseline value. 
Many attempts have been made to reduce errors by imposing 
different assumptions, e.g., regulating localized AIF [34], 
but variances among different models cannot be ignored.  
In contrast to the pharmacokinetic models, kinetic curve 
fitting based feature extraction does not require any input 
variables such as T1 baselines. Instead, the features for dif-
ferentiation between benign and malignant lesions are ex-
tracted from the fitted curve. A recent study found [22] that 
the change of signal intensity is directly related with the 
metabolism of contrast agents in tissue, which can be simu-
lated by a modified logistic regression model. In fact, a 
classic logistic model was originally a probability prediction 
method describing the system with binary response (e.g., 
death or survival) affected by multiple explanatory variables. 
It is capable of simulating a system’s evolution with a single 
S-shaped (sigmoid) output, such as tumor and microbial 
growth [35–37], but fails to predict the washout phase in 
kinetic curves in DCE-MRI. The modified logistic regres-
sion model (eq. (5)) proposed by Moate et al. [22] includes 
an additional structure (p5·t) in the standard logistic func-
tion (eq. (6)) to fit signal intensity curves with a decreasing 
terminal slope, which is able to predict a diverse range of 
gadolinium enhancement patterns.  
















      (6) 
Although no quantitative results were given to separate 
malignant lesions from benign lesions, p2, p4 and p5 were 
extracted to demonstrate the possibility of using logistic 
equations for DCE-MRI data analysis. 
In this work, as a step forward, a dual S-shaped logistic 
model with two diagnostic features,  and , was developed 
(m and n are scaling factors without diagnostic values). It 
not only effectively predicted the wash-out phase of the 
enhancement curves, but also well distinguished between 
malignant and benign lesions by using the derived diagnos-
tic parameter D(, ).  
In this model, the signal pattern that occurs immediately 
following the rapid initial increase is a direct consequence 
of the competition between  and  as two opposing aspects 
of the impact on a kinetic curve’s shape (shown in Figure 5).  
 
 
Figure 5  Schematic drawing of the influence of the two opposite aspects 
of the dual S-shaped logistic model on the shape of kinetic curves. 
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In the enhancement pattern of typical benign tissues, the 
signal intensity continuously increases (type I). The param-
eter  reflects the continuous growth of the signal. For typ-
ical malignant tissues, the signal intensity drops down after 
an initial increase (type III). The decrease of signal intensity 
can be described by . In other situations, a plateau phase is 
shown as a result of the balanced forces on both sides (type 
II).  
However, since  and  represent two opposing aspects 
of the characteristics of a breast lesion, for a more compre-
hensive description, both  and  were employed as fea-
tures to differentiate between benign and malignant breast 
lesions. Most notably, FLD could separate malignant le-
sions from benign lesions in parameter space, showing the 
potential diagnostic value of 2-D features ( and ). In ad-
dition, the extraction procedure of  and  is simple and 
straightforward.  
Although favorable classification results were obtained 
in this study, limitations persist regarding ROI selection. 
Three ROI analysis methods are generally applied in 
DCE-MRI data analysis [38]: The first method employs a 
user-defined trace around the contour of the whole lesion 
and is associated with significant observer variability and 
bias; the second employs pixels with intensity values within 
10% of the maximum; the third one, which was imple-
mented in this study, selects a 9-pixel square in the most 
enhanced part of this region. Although small-sized ROIs 
improve image analysis efficiency, they also introduce low-
er SNR when characterizing the kinetics of the lesion. Fur-
thermore, one small ROI may not be a reliable representa-
tion of the entire region, especially for heterogeneously en-
hanced lesions. In fact, there is not yet a consensus about 
the selection criterion [39]. Finally, it is noted that in this 
work the positioning of the ROI depends on a radiologists’ 
visual assessment in choosing the most enhanced area, 
which may introduce subjective errors into clinical practice. 
It is also worth mentioning that the number of benign and 
malignant lesions included in our study is limited, and 
should be improved in the future. In addition, Kuhl et al. 
[18] have found that there is some overlap between benign 
and malignant lesions in the three-type criteria caused by 
vascular distribution or subtypes with more complicated 
pathological characteristics. For instance, major subtypes of 
malignant lesions include invasive ductal carcinoma (IDC), 
ductal carcinoma in situ (DCIS) and invasive lobular carci-
noma (ILC). For benign lesions, there are fibrocystic change 
(FCC), fibroadenoma, and papilloma [20]. In our research, 
the kinetic characteristics of these subtypes were not con-
sidered. 
In conclusion, this retrospective study applied a dual 
S-shaped logistic model to fit the kinetic curves of breast 
lesions in DCE-MRI. Classification between benign and 
malignant lesions is achieved with sufficient accuracy by 
using the derived diagnostic parameter D(, ) superior to 
that of empirical parameters. The proposed method there-
fore has potential for computer aided diagnosis in breast 
tumors. Preliminary results suggest that it also could be 
useful as a tool for breast cancer screening in the clinic. 
We thank Zhong Hua for her assistance with modifications to the manu-
script. 
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